Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

You’ve supercharged your research process with ACS and Mendeley!

Click to create an ACS ID

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Your Mendeley pairing has expired. Please reconnect
ACS Publications. Most Trusted. Most Cited. Most Read
My Activity

Differential Enzyme-Linked Immunosorbent Assay and Ligand-Binding Mass Spectrometry for Analysis of Biotransformation of Protein Therapeutics: Application to Various FGF21 Modalities

View Author Information
PKDM, Protein Sciences, and §Metabolic Disorders, Amgen Inc., Thousand Oaks, California 91320, United States
*Address: One Amgen Center Dr., MS 30E-3-C, Amgen Inc., Thousand Oaks, CA 91320. Phone: 805/313-6484. Fax: 805/499-9027. E-mail: [email protected]
Cite this: Anal. Chem. 2013, 85, 5, 2731–2738
Publication Date (Web):February 4, 2013
Copyright © 2013 American Chemical Society

    Article Views





    Other access options
    Supporting Info (1)»


    Abstract Image

    Novel protein therapeutics have become increasingly important modalities for treating diseases. Such therapeutics include recombinant fusions of pharmacoactive polypeptides to half-life extenders such as monoclonal antibodies, fragments of antibodies, and albumin. Half-life extension can also be achieved via chemical attachment to polymers such as polyethylene glycol. Any of these therapeutics may be susceptible to biotransformation, most notably in vivo proteolytic truncation, and it is vital to understand this phenomenon during early drug development to ensure correct pharmacokinetic profiling and optimize the in vivo stability through re-engineering. In this paper, we describe an integrated approach that combines differential enzyme-linked immunosorbent assay (ELISA) with ligand-binding-mass spectrometry (LB-MS) to provide a thorough understanding of the biotransformation of novel protein therapeutics. Differential ELISA allows for a fast, high-throughput means to reveal gross in vivo proteolytic liabilities. Ensuing LB-MS analysis provides higher resolution details such as specific vulnerable loci to allow design refinement of the molecule. In this work, the power of the approach is elucidated by application to the optimization of a promising drug candidate, FGF21.

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.


    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.

    Supporting Information

    Jump To

    Additional information as noted in text. This material is available free of charge via the Internet at

    Terms & Conditions

    Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:

    Cited By

    This article is cited by 61 publications.

    1. Menglian Wei, Xue Li, Michael J. Serpe. Stimuli-Responsive Microgel-Based Surface Plasmon Resonance Transducer for Glucose Detection Using a Competitive Assay with Concanavalin A. ACS Applied Polymer Materials 2019, 1 (3) , 519-525.
    2. Lijuan Kang, Raul C. Camacho, Wenyu Li, Katharine D’Aquino, Seohee You, Vanessa Chuo, Naidong Weng, and Wenying Jian . Simultaneous Catabolite Identification and Quantitation of Large Therapeutic Protein at the Intact Level by Immunoaffinity Capture Liquid Chromatography–High-Resolution Mass Spectrometry. Analytical Chemistry 2017, 89 (11) , 6065-6075.
    3. Yue Zhao, Guowen Liu, Xiling Yuan, Jinping Gan, Jon E. Peterson, and Jim X. Shen . Strategy for the Quantitation of a Protein Conjugate via Hybrid Immunocapture-Liquid Chromatography with Sequential HRMS and SRM-Based LC-MS/MS Analyses. Analytical Chemistry 2017, 89 (9) , 5144-5151.
    4. Majlinda Kullolli, Dan A. Rock, and Ji Ma . Immuno-affinity Capture Followed by TMPP N-Terminus Tagging to Study Catabolism of Therapeutic Proteins. Journal of Proteome Research 2017, 16 (2) , 911-919.
    5. Manfred Zell, Christophe Husser, Roland F. Staack, Gregor Jordan, Wolfgang F. Richter, Simone Schadt, and Axel Pähler . In Vivo Biotransformation of the Fusion Protein Tetranectin-Apolipoprotein A1 Analyzed by Ligand-Binding Mass Spectrometry Combined with Quantitation by ELISA. Analytical Chemistry 2016, 88 (23) , 11670-11677.
    6. Kevin D. Cook, Thuy Tran, Veena A. Thomas, Siva Charan Devanaboyina, Dan A. Rock, Josh T. Pearson. Correlation of In Vitro Kinetic Stability to Preclinical In Vivo Pharmacokinetics for a Panel of Anti-PD-1 Monoclonal Antibody Interleukin 21 Mutein Immunocytokines. Drug Metabolism and Disposition 2024, 52 (3) , 228-235.
    7. Mohammad Yasir, Alok Shiomurti Tripathi, Prashant Shukla, Rahul Kumar Maurya. Immunogenicity of Therapeutic Proteins. 2023, 251-273.
    8. Wenying Jian, Cong Wei, and Jinping Gan. Bioanalytical Aspects in Biological Therapeutics. 2022, 277-307.
    9. Jayaprakasam Bolleddula, Kevin Brady, Gerard Bruin, Anthony Lee, Jennifer A. Martin, Markus Walles, Keyang Xu, Tong-Yuan Yang, Xiaochun Zhu, Hongbin Yu. Absorption, Distribution, Metabolism, and Excretion of Therapeutic Proteins: Current Industry Practices and Future Perspectives. Drug Metabolism and Disposition 2022, 50 (6) , 837-845.
    10. Markus Walles, Michael Berna, Wenying Jian, Simon Hauri, Shawna Hengel, Lloyd King, John C. Tran, Cong Wei, Keyang Xu, Xiaochun Zhu. A Cross Company Perspective on the Assessment of Therapeutic Protein Biotransformation. Drug Metabolism and Disposition 2022, 50 (6) , 846-857.
    11. Mei Han, Richard Smith, Dan A. Rock. Capillary Electrophoresis–Mass Spectrometry (CE-MS) by Sheath–Flow Nanospray Interface and Its Use in Biopharmaceutical Applications. 2022, 15-47.
    12. Srikanth Kotapati, Madhura Deshpande, Aarti Jashnani, Dharam Thakkar, Hongwu Xu, Gavin Dollinger. The role of Ligand-Binding Assay and LC–MS in the Bioanalysis of Complex Protein and Oligonucleotide Therapeutics. Bioanalysis 2021, 13 (11) , 931-954.
    13. Morena Martucci, Maria Conte, Rita Ostan, Antonio Chiariello, Filomena Miele, Claudio Franceschi, Stefano Salvioli, Aurelia Santoro, Federica Provini. Both objective and paradoxical insomnia elicit a stress response involving mitokine production. Aging 2020, 12 (11) , 10497-10505.
    14. Yeboah Kwaku Opoku, Zhihang Liu, Justice Afrifa, Mir Hassan Khoso, Guiping Ren, Deshan Li. Therapeutic Role of Fibroblast Growth Factor 21 (FGF21) in the Amelioration of Chronic Diseases. International Journal of Peptide Research and Therapeutics 2020, 26 (1) , 107-119.
    15. Lijuan Kang, Naidong Weng, Wenying Jian. LC–MS bioanalysis of intact proteins and peptides. Biomedical Chromatography 2020, 34 (1)
    16. Simone Schadt, Simon Hauri, Filipe Lopes, Martin R. Edelmann, Roland F. Staack, Roberto Villaseñor, Hubert Kettenberger, Adrian B. Roth, Franz Schuler, Wolfgang F. Richter, Christoph Funk. Are Biotransformation Studies of Therapeutic Proteins Needed? Scientific Considerations and Technical Challenges. Drug Metabolism and Disposition 2019, 47 (12) , 1443-1456.
    17. L.S. Caixeta, S.L. Giesy, C.S. Krumm, J.W. Perfield, A. Butterfield, Y.R. Boisclair. Fibroblast growth factor-21 (FGF21) administration to early-lactating dairy cows. II. Pharmacokinetics, whole-animal performance, and lipid metabolism. Journal of Dairy Science 2019, 102 (12) , 11597-11608.
    18. Robert S. Foti, Kaustav Biswas, Jennifer Aral, Xuhai Be, Loren Berry, Yuan Cheng, Kip Conner, James R. Falsey, Charles Glaus, Brad Herberich, Dean Hickman, Tayo Ikotun, Hongyan Li, Jason Long, Liyue Huang, Les P. Miranda, Justin Murray, Bryan Moyer, Chawita Netirojjanakul, Thomas E. Nixey, Kelvin Sham, Marcus Soto, Christopher M. Tegley, Linh Tran, Bin Wu, Lin Yin, Dan A. Rock. Use of Cryopreserved Hepatocytes as Part of an Integrated Strategy to Characterize In Vivo Clearance for Peptide-Antibody Conjugate Inhibitors of Nav1.7 in Preclinical Species. Drug Metabolism and Disposition 2019, 47 (10) , 1111-1121.
    19. Fengping Li, Yan Weng, Guodong Zhang, Xiaogang Han, Dongmei Li, Hendrik Neubert. Characterization and Quantification of an Fc-FGF21 Fusion Protein in Rat Serum Using Immunoaffinity LC-MS. The AAPS Journal 2019, 21 (5)
    20. Yan Weng, Tetsuya Ishino, Annette Sievers, Saswata Talukdar, Jeffrey R. Chabot, Amy Tam, Weili Duan, Kelvin Kerns, Eric Sousa, Tao He, Alison Logan, Darwin Lee, Dongmei Li, Yingjiang Zhou, Barbara Bernardo, Alison Joyce, Mania Kavosi, Denise M. O’Hara, Tracey Clark, Jie Guo, Craig Giragossian, Mark Stahl, Roberto A. Calle, Ron Kriz, Will Somers, Laura Lin. Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing. Scientific Reports 2018, 8 (1)
    21. Biraj Parmar, Jo E. Lewis, Ricardo J. Samms, Francis J. P. Ebling, Christine C. Cheng, Andrew C. Adams, Joanne Mallinson, Scott Cooper, Tariq Taylor, Reza Ghasemi, Francis B. Stephens, Kostas Tsintzas. Eccentric exercise increases circulating fibroblast activation protein α but not bioactive fibroblast growth factor 21 in healthy humans. Experimental Physiology 2018, 103 (6) , 876-883.
    22. Cong Wei, Dian Su, Jian Wang, Wenying Jian, Donglu Zhang. LC–MS Challenges in Characterizing and Quantifying Monoclonal Antibodies (mAb) and Antibody-Drug Conjugates (ADC) in Biological Samples. Current Pharmacology Reports 2018, 4 (1) , 45-63.
    23. Yue Zhao, Guowen Liu, Suk Kwok, Barry R Jones, Jane Liu, David Marchisin, Philip E Joyce, Jon Peterson, Jim X Shen. Highly Selective and Sensitive Measurement of Active forms of FGF21 Using Novel Immunocapture Enrichment with LC–MS/MS. Bioanalysis 2018, 10 (1) , 23-33.
    24. Mei Han, Josh T. Pearson, Yunan Wang, Dwight Winters, Marcus Soto, Dan A. Rock, Brooke M. Rock. Immunoaffinity capture coupled with capillary electrophoresis - mass spectrometry to study therapeutic protein stability in vivo. Analytical Biochemistry 2017, 539 , 118-126.
    25. Miao Qu, Bo An, Shichen Shen, Ming Zhang, Xiaomeng Shen, Xiaotao Duan, Joseph P. Balthasar, Jun Qu. Qualitative and quantitative characterization of protein biotherapeutics with liquid chromatography mass spectrometry. Mass Spectrometry Reviews 2017, 36 (6) , 734-754.
    26. Ricardo J Samms, Jo E Lewis, Luke Norton, Francis B Stephens, Christopher J Gaffney, Tony Butterfield, Dennis P Smith, Christine C Cheng, James W Perfield, Andrew C Adams, Francis J P Ebling, Kostas Tsintzas. FGF21 Is an Insulin-Dependent Postprandial Hormone in Adult Humans. The Journal of Clinical Endocrinology & Metabolism 2017, 102 (10) , 3806-3813.
    27. Shaolian Zhou, Faye Vazvaei, Luca Ferrari, Jun Qu. Practical Considerations in Enhancing LC–MS Sensitivity for Therapeutic Protein Bioanalysis. Bioanalysis 2017, 9 (18) , 1353-1356.
    28. Bradley L. Ackermann, Michael J. Berna. The Application of Immunoaffinity‐Based Mass Spectrometry to Characterize Protein Biomarkers and Biotherapeutics. 2017, 67-89.
    29. G. Li, J. Yin, J. Fu, L. Li, S.F.A. Grant, C. Li, M. Li, J. Mi, M. Li, S. Gao. FGF21 deficiency is associated with childhood obesity, insulin resistance and hypoadiponectinaemia: The BCAMS Study. Diabetes & Metabolism 2017, 43 (3) , 253-260.
    30. Shanaka Stanislaus, Randy Hecht, Junming Yie, Todd Hager, Michael Hall, Chris Spahr, Wei Wang, Jennifer Weiszmann, Yang Li, Liying Deng, Dwight Winters, Stephen Smith, Lei Zhou, Yuesheng Li, Murielle M. Véniant, Jing Xu. A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward β-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys. Endocrinology 2017, 158 (5) , 1314-1327.
    31. Xiaodong Li, Shanaka Stanislaus, Frank Asuncion, Qing-Tian Niu, Narumol Chinookoswong, Kelly Villasenor, Jin Wang, Philip Wong, Rogely Boyce, Denise Dwyer, Chun-Ya Han, Michelle M Chen, Benxian Liu, Marina Stolina, Hua Zhu Ke, Michael S Ominsky, Murielle M Véniant, Jing Xu. FGF21 Is Not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPARα and PPARγ Agonists. Journal of Bone and Mineral Research 2017, 32 (4) , 834-845.
    32. A. Kharitonenkov, R. DiMarchi. Fibroblast growth factor 21 night watch: advances and uncertainties in the field. Journal of Internal Medicine 2017, 281 (3) , 233-246.
    33. Rong Liu, Brian Hoffpauir, Shannon D Chilewski, Janice Gamberdella, Uma Kavita, Jia Duo, Carol Gleason, Yan Zhang, Renuka Pillutla, Binodh DeSilva, Lora Hamuro. Accelerating Regulated Bioanalysis for Biotherapeutics: Case Examples Using a Microfluidic Ligand Binding Assay Platform. The AAPS Journal 2017, 19 (1) , 82-91.
    34. Brian Rago, Tracey Clark, Lindsay King, Jenny Zhang, L Nathan Tumey, Fengping Li, Frank Barletta, Cong Wei, Mauricio Leal, Steve Hansel, Xiaogang Han. Calculated Conjugated Payload from Immunoassay and LC–MS Intact Protein Analysis Measurements of Antibody-Drug Conjugate. Bioanalysis 2016, 8 (21) , 2205-2217.
    35. Miguel Angel Sánchez-Garrido, Kirk M. Habegger, Christoffer Clemmensen, Cassie Holleman, Timo D. Müller, Diego Perez-Tilve, Pengyun Li, Archita S. Agrawal, Brian Finan, Daniel J. Drucker, Matthias H. Tschöp, Richard D. DiMarchi, Alexei Kharitonenkov. Fibroblast activation protein (FAP) as a novel metabolic target. Molecular Metabolism 2016, 5 (10) , 1015-1024.
    36. Matthew P. Gillum, Matthew J. Potthoff. FAP finds FGF21 easy to digest. Biochemical Journal 2016, 473 (9) , 1125-1127.
    37. Eliza N Fung, Peter Bryan, Alexander Kozhich. Techniques for Quantitative LC–MS/MS Analysis of Protein Therapeutics: Advances in Enzyme Digestion and Immunocapture. Bioanalysis 2016, 8 (8) , 847-856.
    38. Eugene Y. Zhen, Zhaoyan Jin, Bradley L. Ackermann, Melissa K. Thomas, Jesus A. Gutierrez. Circulating FGF21 proteolytic processing mediated by fibroblast activation protein. Biochemical Journal 2016, 473 (5) , 605-614.
    39. D.M. Kilkenny, J.V. Rocheleau. The FGF21 Receptor Signaling Complex. 2016, 17-58.
    40. Yan J Zhang, Linlin Luo, Dharmesh D Desai. Overview on Biotherapeutic Proteins: Impact on Bioanalysis. Bioanalysis 2016, 8 (1) , 1-9.
    41. Jean W Lee. Generic Method Approaches for Monoclonal Antibody Therapeutics Analysis Using Both Ligand Binding and LC–MS/MS Techniques. Bioanalysis 2016, 8 (1) , 19-27.
    42. Josh T Pearson, Dan A Rock. Bioanalytical approaches to assess the proteolytic stability of therapeutic fusion proteins. Bioanalysis 2015, 7 (23) , 3035-3051.
    43. Jun Zhang, Yang Li. Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders. Frontiers in Endocrinology 2015, 6
    44. Alexei Kharitonenkov, Richard DiMarchi. FGF21 Revolutions: Recent Advances Illuminating FGF21 Biology and Medicinal Properties. Trends in Endocrinology & Metabolism 2015, 26 (11) , 608-617.
    45. Dhaval K. Shah. Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics. Journal of Pharmacokinetics and Pharmacodynamics 2015, 42 (5) , 553-571.
    46. Craig Giragossian, Chandra Vage, Jun Li, Kathleen Pelletier, Nicole Piché-Nicholas, Manoj Rajadhyaksha, Jennifer Liras, Alison Logan, Roberto A. Calle, Yan Weng. Mechanistic Investigation of the Preclinical Pharmacokinetics and Interspecies Scaling of PF-05231023, a Fibroblast Growth Factor 21–Antibody Protein Conjugate. Drug Metabolism and Disposition 2015, 43 (6) , 803-811.
    47. Chris Macaraeg, Jessica Ortiz, Dominador Calamba, Mark Ma. Serum sample stability in ligand-binding assays: challenges in assessments of long-term, bench-top and multiple freeze–thaw. Bioanalysis 2015, 7 (11) , 1361-1370.
    48. Yan Weng, Jeffrey R. Chabot, Barbara Bernardo, Qingyun Yan, Yimin Zhu, Martin B. Brenner, Chandra Vage, Alison Logan, Roberto Calle, Saswata Talukdar, . Pharmacokinetics (PK), Pharmacodynamics (PD) and Integrated PK/PD Modeling of a Novel Long Acting FGF21 Clinical Candidate PF-05231023 in Diet-Induced Obese and Leptin-Deficient Obese Mice. PLOS ONE 2015, 10 (3) , e0119104.
    49. Michael P. Hall. Biotransformation and In Vivo Stability of Protein Biotherapeutics: Impact on Candidate Selection and Pharmacokinetic Profiling. Drug Metabolism and Disposition 2014, 42 (11) , 1873-1880.
    50. Eliza N Fung, Frank Zambito, Jonathan Haulenbeek, Steven P Piccoli, Yan Zhang, Binodh DeSilva, Mark Arnold, Alexander Kozhich. Targeting an Acid Labile Aspartyl–Prolyl Amide Bond as A Viable Alternative to Trypsin Digestion to Generate A Surrogate Peptide for LC–MS/MS Analysis. Bioanalysis 2014, 6 (22) , 2985-2998.
    51. Eric Ezan, François Becher, François Fenaille. Assessment of the metabolism of therapeutic proteins and antibodies. Expert Opinion on Drug Metabolism & Toxicology 2014, 10 (8) , 1079-1091.
    52. Yan J Zhang, Timothy V Olah, Jianing Zeng. The Integration of Ligand Binding and LC-MS-Based Assays Into Bioanalytical Strategies for Protein Analysis. Bioanalysis 2014, 6 (13) , 1827-1841.
    53. Alexei Kharitonenkov, Andrew C. Adams. Inventing new medicines: The FGF21 story. Molecular Metabolism 2014, 3 (3) , 221-229.
    54. Ruth E. Gimeno, David E. Moller. FGF21-based pharmacotherapy – potential utility for metabolic disorders. Trends in Endocrinology & Metabolism 2014, 25 (6) , 303-311.
    55. Ricardo J. Samms, Maxine J. Fowler, Scott Cooper, Paul Emmerson, Tamer Coskun, Andrew C. Adams, Alexei Kharitonenkov, Kostas Tsintzas, Francis J.P. Ebling. Photoperiodic regulation of FGF21 production in the Siberian hamster. Hormones and Behavior 2014, 66 (1) , 180-185.
    56. Jun Zhang, Yang Li. Fibroblast growth factor 21, the endocrine FGF pathway and novel treatments for metabolic syndrome. Drug Discovery Today 2014, 19 (5) , 579-589.
    57. Jean W Lee. Orthogonal Tools to Help Determine The Required Selectivity of Ligand-Binding Assays in Drug Development. Bioanalysis 2014, 6 (8) , 1037-1040.
    58. P. J. Antonellis, A. Kharitonenkov, A. C. Adams. Physiology and Endocrinology Symposium: FGF21: Insights into mechanism of action from preclinical studies1,2. Journal of Animal Science 2014, 92 (2) , 407-413.
    59. Jean W Lee. ADME of Monoclonal Antibody Biotherapeutics: Knowledge Gaps and Emerging Tools. Bioanalysis 2013, 5 (16) , 2003-2014.
    60. Eric Ezan. Pharmacokinetic studies of protein drugs: Past, present and future. Advanced Drug Delivery Reviews 2013, 65 (8) , 1065-1073.
    61. Christopher H. Becker. Laser Resonant and Nonresonant Photoionization of Sputtered Neutrals. 1991, 273-310.